Are Halberd Corporation (HALB) Prospects Worsening?

Halberd Corporation (OTC:HALB) stabilized on Friday slipping just -0.96% to close the session at $0.0206. The volume of HALB stock was 1.06M in contrast with its Average Weekly volume of 4.04M. A significant development in a laboratory testing helped HALB stock stabilized on the day.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


Which HALB experiment concocted empowering results?

Halberd is an inventive biotech organization zeroed in on creating therapies through its obtained elite licenses, licenses, and temporary patent applications for sicknesses including and restricted to; PTSD, CTE, malignant growth, blood-borne, and cerebrospinal liquid related infections. HALB is a holding organization and securing vehicle for set up organizations. HALB likewise looks for different types of COVID-19 help including for testing, deterrent and mitigating immediate and guarantee impacts.

Halberd last Thursday declared that it has had the option to effectively kill Beta Amyloid and Interleukin-4 (IL-4) from engineered cerebral spinal liquid (CSF) in its most recent in-vitro lab testing.

  • HALB’s most recent testing achievements support its long-standing objective of effectively annihilating all of the best ten objective antigens from a static inspecting of CSF, accordingly allowing control of these objective antigens to the recommended homeostasis level under doctor care.
  • HALB progress is connected to neurodegenerative illnesses which have remained basically untreated throughout the long term.
  • Beta-Amyloid is broadly perceived to be a main consideration of Alzheimer’s Disease.
  • HALB’s interesting capacity to destroy Beta-Amyloid, combined with its annihilation of IL-4 and its past end of TNF-Alpha, Phosphorylated-Tau, other objective antigens, and fiery cytokines from CSF, persuades HALB to think it has accomplished unrivaled advancement.
  • HALB ebb and flow progress is toward easing back or forestalling the beginning of Alzheimer’s Disease and other neurodegenerative illnesses, like Epilepsy, Lou Gehrig’s Disease (ALS), PTSD, Traumatic Brain Injury, and Chronic Traumatic Encephalopathy.
  • Albeit relative, serious information has been hard to get, HALB accepts that this is a really stupendous outcome in contrast with some other cutthroat guaranteed treatments accessible anyplace on the planet.
  • All that HALB can decide from contest is that it guarantees to dispose of just 5-15% of Beta-Amyloid from CSF inside a month of costly treatment.
  • The effective in-vitro lab tests demonstrates that HALB innovation can be utilized to manage any of the best ten neurodegenerative connected designated antigens to OK levels, as coordinated by going to doctors.
  • The meaning of these proceeding with series of tests is that HALB’s three gave licenses just as its 20 related temporary patent applications demonstrate that this remarkable innovation has a place solely with HALB.

HALB’s other achievement:

Halberd Corporation (HALB) as of late become enrolled with the Federal Government’s System for Award Management permitting HALB to offer on Federal agreements and direct business with the Federal government in the space of Research and Development in Biotechnology, and Food (Health) Supplement Stores. This makes the way for HALB to give items and administrations to individuals from the military and different government organizations.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles